Trial Profile

A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Delpazolid (Primary) ; Linezolid; Rifampicin/isoniazid/pyrazinamide/ethambutol
Indications Pulmonary tuberculosis
Focus Therapeutic Use
Sponsors LegoChem Biosciences; LigaChem Biosciences

06 Dec 2021 Results assessing the bactericidal activity, safety, and pharmacokinetics of delpazolid in patients with pulmonary tuberculosis (TB) published in the Antimicrobial Agents and Chemotherapy
04 Feb 2020 Status changed from recruiting to completed.
14 Aug 2019 Planned End Date changed from 1 Dec 2018 to 1 Feb 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com